Development of a Transgenic *Flammulina velutipes* Oral Vaccine for Hepatitis B

Li-Hsin Huang¹, Hao-Yeh Lin², Ying-Tzu Lyu¹, Chiau-Ling Gung¹ and Ching-Tsan Huang²*

¹MycoMagic Biotechnology Co. Ltd., 8F-1, 12, Lane 270, Sec. 3, Beishen Road, New Taipei City, Taiwan
²Department of Biochemical Science and Technology, National Taiwan University, 1, Sec. 4, Roosevelt Road, Taipei, Taiwan

Received: 24 May 2018
Accepted: 31 January 2019

SUMMARY

Orally administered fungal vaccines show promise for the prevention of infectious diseases. Edible mushrooms are deemed appropriate hosts to produce oral vaccines due to their low production cost and low risk of gene contamination. However, their low expression level of antigens has limited the potential development of oral vaccines using mushrooms. The low expression level might result from impurity of the transgenic mycelia since dikaryotic mycelia are commonly used as transformation materials. In this study, stable transgenic hepatitis B virus surface antigen (HBsAg) in *Flammulina velutipes* transformants was obtained by *Agrobacterium*-mediated transformation, followed by fruiting and basidiospore mating. The formation of HBsAg was detected by western blot analysis. The expression levels of HBsAg in transgenic *F. velutipes* fruiting bodies were (129.3±15.1), (110.9±1.7) and (161.1±8.5) ng/g total soluble protein. However, the values may be underestimated due to incomplete protein extraction. Two of the four pigs in the experimental group produced positive anti-HBsAg-specific IgG after being fed the HBsAg transgenic *F. velutipes* fruiting bodies for 20 weeks, while no anti-HBsAg antibody was detected in the control group. One of the positive pigs had HBsAg titres of 5.36 and 14.9 mIU/mL in weeks 10 and 14, respectively, but expression faded thereafter. The other positive pig displayed HBsAg titres of 9.75, 17.86 and 39.87 mIU/mL in weeks 14, 18 and 20, respectively. The successful immunogenicity in pigs fed transgenic *F. velutipes* fruiting bodies demonstrated the potential of using the fungus as an oral vaccine.

Key words: *Agrobacterium*-mediated transformation, *Flammulina velutipes*, hepatitis B, mating, oral vaccine

INTRODUCTION

Although vaccinations have saved millions of lives from infectious diseases, full implementation of global vaccination remains a challenge due to the relatively high costs of conventional vaccinations incurred by mass production, refrigeration and transportation, as well as by training and compensating personnel for their administration. To overcome these problems, many efforts have been devoted to the development of novel and cost-effective vaccination procedures and technologies. In addition to injected vaccines, oral administration of either raw materials or extracts from transgenic plants, spirulina or yeasts has been reported to stimulate systemic and mucosal immunity (1).

Oral vaccines are known to stimulate multiple types of immunity, including mucosal and humoral immunity (2). Plant-based oral vaccines were first proposed two decades ago (3). The use of transgenic fruits and vegetables for the expression of recombinant protein antigens as oral vaccines has become an attractive topic in plant molecular farming (1,4). For example, many efforts have been made to develop hepatitis B oral vaccines by expressing hepatitis B virus surface antigen (HBsAg) in transgenic plants such as tobacco, tomato, potato, banana, tomatillo and rice (5-12). In addition to plants, edible mushrooms are also appropriate hosts for the development of oral vaccines (13). Using transgenic mushrooms as oral vaccines has all the advantages of a plant-based system coupled with unique benefits, such as complete duplication, fast growth, scaled-up production under controlled conditions.
conditions and less gene contamination. A previous study demonstrated the effectiveness of extracts of mycelia derived from edible mushrooms as adjuvants for intranasal influenza vaccines (14). Pérez-Martínez et al. (15) provided a comprehensive review on the use of Pleurotus as carrier of oral subunit vaccines. While mushroom-based oral vaccines seem promising, the low expression level of antigens and the instability of the transformants limit the development of mushroom molecular farming. Previously, we demonstrated that heterologous protein expression in the enoki mushroom *Flammulina velutipes* is notably enhanced by using 2A peptide-mediated cleavage to co-express multiple copies of a single gene (16). Using this polycistronic expression strategy, enterovirus 71 virus-like particles were successfully produced in transgenic *F. velutipes* (17).

Mating and fruiting body formation are sexual stages in the life cycle of basidiomycete fungi and lead to karyogamy, meiosis and basidiospore formation. *F. velutipes* is a heterothallic basidiomycete fungus whose life cycle is characterized by haploid and diploid stages (18). *F. velutipes* has a tetrapolar mating type system that generates basidiospores with four possible mating types. After germination, the haploid spores develop into monokaryotic mycelia with AxBx, AxBy, AyBx or AyBy mating types. Although single mating types have been known to produce fruiting bodies under severe stress, most fruiting requires the plasmogamy of two genetically different monokaryotic mycelia, AxBx/AyBy or AxBy/AyBx, to form the dikaryotic mycelia that consist of two nuclei in a cell and the structure of clamp connection (19). The generation of transgenic mushrooms usually involves *Agrobacterium*-mediated transformation using modified mycelial pellets, followed by the selection of transformants under appropriate pressures (17). Transformants are selected if the foreign gene is inserted into the chromosomal DNA in at least one nucleus of the mycelia. Consequently, the expression level and stability of heterologous genes are reduced if the transformants contain both transgenic and non-transgenic cells. Therefore, it is crucial to obtain transformants containing the transgene in all nuclei.

In this study, stable HBsAg transgenic *F. velutipes* transformants were obtained by *Agrobacterium*-mediated transformation, followed by fruiting and basidiospore mating. We demonstrated that specific immunogenicity was detected in pigs after feeding HBsAg transgenic *F. velutipes* fruiting bodies for a period of time.

MATERIALS AND METHODS

**Strains and media**

*Flammulina velutipes* BCRC 930110, a patented strain deposited at the Bioresource Collection and Research Centre (Hsinchu, Taiwan), was grown and maintained on complete yeast medium (CYM) agar or in broth containing 0.2 % tryptone (BD Bioscience, Sparks, MD, USA), 0.2 % yeast extract (Bio Basic, Amherst, NY, USA), 1 % maltose (Sigma-Aldrich, Merck, St. Louis, MO, USA), and 2 % glucose (Bio Basic) at 25 °C. *Escherichia coli* DH5α (Gibco BRL, Life Technologies, Grand Island, NY, USA), which was used for DNA manipulation and plasmid conservation, was grown in Luria-Bertani (LB) medium (Sigma-Aldrich, Merck) at 37 °C. *Agrobacterium tumefaciens* strain LBA4404, kindly provided by Dr Yee-Yung Chang, Agricultural Biotechnology Research Centre, Academia Sinica (Taipei, Taiwan), was used for transformations and was grown in LB medium at 28 °C.

**Plasmid construction**

A promoter region of the *Agaricus bisporus* glyceraldehyde-3-phosphate dehydrogenase (*Gpd*) gene was amplified from the genome of *A. bisporus* by using primers Agpd-f (5’-TTAAGAGGTCCGCAAGTAGATTGA-3’) and Agpd-r (5´-ATGTGTTGTGCGATAGCGG-3’). The plasmid pGEM-Agpd was constructed by cloning the Agpd promoter into a pGEM-T Easy vector (Promega, Madison, WI, USA). The *E. coli* hygromycin B phosphotransferase (*hpt*) gene with cauliflower mosaic virus (CaMV) 35S terminator was amplified from pCAMBIA 1300 (Cambia, Canberra, Australia) using primers Spel-Hpt-f (5´-ACTAGTATGAAAAAGCCTGAACTCACC-3’) and Pstl-CaMV 35S terminator-r (5´-TTACAAATATTTAATACAGAGTCGG-3’). Then, the amplified fragment was cloned into a pGEM-Agpd vector by restriction enzymes Spel and Pstl. The backbone plasmid p0390-AH was constructed by introducing the hpt and CaMV 35S terminator gene driven by Agpd promoter into the pCAMBIA0390 (p0390) vector (CAMBIA) by using restriction enzymes Ncol and Pstl. The *F. velutipes* gpd (*Fgd*) promoter was amplified from the *F. velutipes* genome by using primers Ncol-Fgd-f (5´-CCATGGGCGGATCTCGCTCTA-3’) and KpnI-Fgd-r (5´-CGGTACCTGGTAGATGGAGA-3’). The plasmid pGEM-Fgd was constructed by cloning the Fgd promoter into a pGEM-T Easy vector. The codon usage of hepatitis B virus surface antigen (*HbsAg*) derived from plasmid pRcCMV-HBs(S) (Aldevron, Fargo, ND, USA) was modified according to the codon bias of *F. velutipes*, and an endoplasmic reticulum (ER) retention signal (HDEL) was fused to the C terminus of HbsAg protein to improve its expression. The gene of HbsAg was amplified by primers KpnI-HBs-f (5´-GGTACCAGATGGAACATCATCAT-3’) and BstElI-HBs-r (5´-GGTACCCCTAGGTGATAGCGG-3’) and cloned into a pGEM-Fgd by restriction enzymes KpnI and BstElI. The construct carrying the gene encoding HbsAg (accession number MG717400) driven by the *F. velutipes* gpd promoter was cut from pGEM-Fgd by restriction enzymes Ncol and BstElI inserted into p0390-AH, and the resulting plasmid was designated as p0390-AH-FmHB. A map of the plasmid constructs is shown in Fig. 1.

**Transformation procedure**

*Agrobacterium*-mediated transformation (AMT) was performed as described by Chen et al. (20) with minor modifications. The p0390 or p0390-AH or p0390-AH-FmHB constructs were introduced into *A. tumefaciens* by electroporation (ECM 630; BTX, San Diego, CA, USA). The *A. tumefaciens* strains harbouring the target plasmids were cultivated in LB medium

106 FTB Food Technology & Biotechnology January-March 2019 | Vol. 57 | No. 1
containing 50 μg/mL of kanamycin (MDBio Inc., Taipei, Taiwan) for 24 h at 28 °C, with shaking at 220 rpm, in an incubator (model S-300R; FIRSTEK, New Taipei City, Taiwan). The strains were then mixed with modified mycelial pellets (MMPs) of *F. velutipes* for 24 h at 23 °C in an induction medium containing 11.8 mM dipotassium phosphate, 10.7 mM monopotassium phosphate, 2 mM magnesium sulfate, 0.6 mM calcium chloride, 9 μM iron(II) sulfate, 43.7 mM 2-(N-morpholino)-ethanesulfonic acid (MES; pH=5.3), 200 μM acetylsyringone (all from Sigma-Aldrich, Merck), 2.5 mM sodium chloride, 3.8 mM ammonium sulfate, 0.18 % glucose (all from Bio Basic), and 0.5 % (m/V) glycerol (Riedel-de Haën; Honeywell, Morris, NJ, USA). After incubation, the MMPs were transferred to fresh induction medium agar plates and incubated at 23 °C for 3-6 days. Then, the treated MMPs were washed with sterile water five times to remove bacteria, transferred to selective agar plates containing 30 μg/mL hygromycin B (Thermo Fisher Scientific, San Jose, CA, USA) and 200 mM cepotaxime (MDBio Inc.) and incubated at 25 °C for 2-3 weeks until hygromycin B-resistant mycelia of *F. velutipes* appeared.

**PCR analysis**

*F. velutipes* transformants grown on selective agar plates were subsequently screened via PCR analysis to confirm the integration of HBsAg gene into the genomes. The HBsAg gene fragment was amplified by 96-well thermal cycler (Veriti™ 9902; Applied Biosystems, Foster City, CA, USA) with primers HBsAg-f (5’-GTCGACGGGTACCCAGTTGATGCCATGAT-3’) and HBsAg-r (5’-GTCGACGGGTACCCAGTTGATGCCATGAT-3’). Genomic DNA was extracted from four-week-old mycelia that were grown in CYM broth with 30 μg/mL hygromycin B, using the CTAB-mini DNA extraction method with minor modifications (21). The residual RNA in the isolated DNA was removed by treatment with DNase-free RNase A (GMbiolab Co., Ltd., Taipei, Taiwan).

**Mycelium staining**

Monokaryotic or dikaryotic mycelia on slides were fixed with 37 % formaldehyde (Sigma-Aldrich, Merck) for 2 min at room temperature. Samples were then rinsed twice with sterile distilled water before incubation for 5 min at room temperature with 1 μg/mL 4',6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich, Merck). The slides were observed by a fluorescence microscope (Eclipse E600; Nikon, Kanagawa, Japan) fitted with a Nikon UV-2A filter (330-380 nm excitation filter, 400 nm dichroic filter, and 420 nm barrier filter).

**Fruiting and mating of transformants**

The *F. velutipes* transformants were stabilized via mating. The fruiting body development procedure was described previously (22). Capped polypropylene bottles containing 70 % sawdust and 30 % rice bran were purchased from Wanshen farm (Changhua, Taiwan), autoclaved for 1 h, then inoculated with mycelial plugs and incubated at 23 °C for approx. 3 to 4 weeks. After the vegetative mycelia had grown throughout the substrate, fruiting was induced by water addition, air exposure, and temperature change from 25 to 8 °C. The conditions were kept humid during the fruiting period by watering every other day with sterile distilled water. The basidiospores were collected in a sealed plate (9-cm Petri dishes) from the mature fruiting bodies which were verified by DAPI staining. Mating was conducted by placing two mycelial plugs on the same CYM agar plate for weeks at 23 °C. Successful mating was also confirmed by the formation of clamp connections and the presence of two nuclei in a cell. Three dikaryotic transformants were randomly picked for further analysis.

**Western blot analysis**

For western blot analysis of HBsAg, the fruiting bodies of the *F. velutipes* transformants and of wild-type controls were collected and ground in liquid nitrogen with a mortar and pestle. A total of 40 mg of sample powder was mixed on ice for 1 h with 0.5 mL of protein extraction buffer containing 50 mM potassium phosphate (pH=7.4; Sigma-Aldrich, Merck), 0.1 % Triton X-100 (J.T.Baker, Avantor, Radnor, PA, USA), 300 mM sodium chloride (Bio Basic), and 1 mM phenylmethane sulfonyl fluoride (PMSF; Sigma-Aldrich, Merck). The total soluble protein (TSP) was obtained by centrifugation (13 000×g for 30 min) and subsequently used for Western blot analysis.
for 30 min at 4 °C using Thermo Scientific Sorvall® Legend Mach 1.6 R tabletop centrifuge (Thermo Fisher Scientific), boiled for 20 min with sample buffer containing 50 mM Tris-HCl (pH=7.4; Bio-Rad, Hercules, CA, USA), 2 % sodium dodecyl sulfate (SDS), 0.1 % bromophenol blue, 10 % glycerol, 400 mM dithiothreitol (DTT) and 800 mM 2-mercaptoethanol (all from Sigma-Aldrich, Merck), and separated by 12 % sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The protein samples were transferred via a Trans-Blot® electrophoretic transfer cell (Bio-Rad) to a polyvinylidene difluoride (PVDF) membrane (Millipore, Bedford, MA, USA). Protein was detected using a mouse monoclonal anti-HBsAg antibody (ab9193; Abcam, Taipei, Taiwan) and a goat anti-mouse IgG antibody-conjugated alkaline phosphatase (ab97020; Abcam) in a reaction with 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (BCIP/NBT) (PerkinElmer, Foster City, CA, USA) as described by the manufacturers.

HBsAg quantification

HBsAg was detected using the SURASE B-96 kit (General Biologicals Corporation, Taipei, Taiwan) according to the manufacturer’s instructions. Plate wells coated with anti-HBsAg antibody were incubated with 50 μL of TSP and anti-HBsAg antibody-conjugated peroxidase for 90 min at 37 °C. Each assay was repeated in triplicate for each plate. After the incubation, the plate wells were washed six times with phosphate buffer (provided in the kit), then 100 μL of the TMB One Component HRP microwell substrate (BioFX Laboratories Inc., Owings Mills, MD, USA) was added to each well, and the plates were incubated for 30 min at 37 °C. The reaction was stopped by the addition of 2 M sulfuric acid (provided in the kit), and the absorbance at 450 nm of each well was measured using a 96-well plate reader (VERSAmax™; Molecular Devices, LLC, San Jose, CA, USA). Protein concentrations were determined using the Pierce™ BCA Protein Assay Kit (Pierce Biotechnology, Thermo Fisher Scientific, Rockford, IL, USA). The SURASE B-96 quantitative standard panel is included with each assay.

Animal tests

The animal tests were conducted at Animal Technology Laboratories, Agriculture Technology Research Institute (Chunan, Taiwan). Specific pathogen-free (SPF) pigs, four males and three females, three weeks old, 19 kg of average body mass, were provided by the Cheng-Yu Pig Farm (Hsinchu City, Taiwan). The fruiting bodies of transgenic F. velutipes with the highest HBsAg content were used for the animal tests. Four pigs, two males and two females, in the experimental group were each fed with 9 g dry transgenic F. velutipes fruiting body powder every 3 days for 6 consecutive weeks, followed by feeding once a week for another 14 consecutive weeks. Another three pigs fed with wild-type F. velutipes were used as the control group. The fruiting body powder was mixed with 2 kg fodder composed of corn, soybean and rice bran (Cheng-Yu Pig Farm), and left in the cage for 24 h or until all food was consumed. Regular fodder was used throughout the experiment. Starting from the sixth week, blood samples were collected periodically for antibody assay.

Measurement of anti-HBsAg antibodies

HBsAg antibodies were detected with Elecsys anti-HBs (Roche, Basel, Switzerland) electrochemiluminescence immunoassay according to the manufacturer’s instructions using Modular E170 immunology analyzer (Roche). Anti-HBsAg antibodies in the sample, biotinylated HBsAg, and HBsAg labelled with a ruthenium complex reacted to form a sandwich complex. After the addition of streptavidin-coated microparticles, the complex bound to the solid phase via interaction of biotin and streptavidin. The reaction mixture was aspirated into the measuring cell where the microparticles were magnetically captured onto the surface of the electrode. Application of a voltage to the electrode induced chemiluminescent emission which was measured by Modular E170 immunology analyzer (Roche). Results were determined via a calibration curve which was instrument-specifically generated by 2-point calibration and a master curve provided via the reagent barcode, calculated in milli-international units per volume (mIU/mL), and reported as positive when the value was more than 10 mIU/mL.

Statistical analysis

Least significant difference (LSD at p=0.05) test was used to identify significant differences of the expression level among three transformants. Significant difference was defined at p<0.05.

RESULTS AND DISCUSSION

F. velutipes transformation

A. tumefaciens containing p0390, p0390-AH or p0390-AH-FmHB was co-cultivated with F. velutipes MMPs in induction medium for 5–7 days and then transferred to selective agar plates containing 30 μg/mL hygromycin B. The plasmids p0390 and p0390-AH were used as negative and positive control, respectively. As shown in Fig. 2, hygromycin B-resistant mycelia appeared approx. 2–4 weeks after the transfer to the selective agar plates; however, F. velutipes MMPs co-cultivated with A. tumefaciens carrying the empty vector p0390 failed to grow. To confirm the stability of the putative transformants carrying the plasmid p0390-AH-FmHB, they were subcultured three times on the agar plates under selection pressure to ensure that the hygromycin B resistance gene and the HBsAg gene were stably expressed in F. velutipes. Even though the transformants can stably grow on the selective agar plates, their mycelia might be composed of both transgenic and non-transgenic cells. To resolve this problem, mushroom fruiting and basidiospore mating were conducted.
Transformant fruiting and mating

Two putative transformants were selected as the parental strains for fruiting. The fruiting bodies of transformants 1 and 2 were cultivated and the basidiospores were collected. The basidiospores were separated by spreading them onto CYM agar plates containing 30 μg/mL hygromycin B to form monokaryotic mycelia. PCR analysis served to investigate the presence of the HBsAg gene. Fig. 3 illustrates that HBsAg gene was stably maintained in the parental (Fig. 3a) and the filial generation (Fig. 3b) of dikaryotic transformants, and in the monokaryotic mycelium transformants derived from parental generation (Fig. 3c). The successful mating was checked by the clamp connection and by compatible growth of two monokaryotic mycelial plugs. No clamp connections were observed in the monokaryotic mycelia (Fig. 4a). Mating was conducted by placing two monokaryotic mycelial plugs on the same CYM agar plate containing 30 μg/mL hygromycin B and incubating at 23 °C for 3 weeks. The successful mating was confirmed by compatible growth between two monokaryotic mycelial plugs (Fig. 4b) and clamp connections (Fig. 4c). These results show that both nuclei in each pure cell of the filial dikaryotic mycelia contained the target gene. The dikaryotic mycelia containing the HBsAg gene remained stable after repeated subculture (data not shown). The fruiting bodies of the stable dikaryotic mycelia were cultivated for further HBsAg analysis and for the animal tests.

HBsAg quantification and qualification via ELISA and western blot analysis

The western blot analysis of three HBsAg transgenic F. velutipes fruiting bodies is shown in Fig. 5. Immunoblotting with the monoclonal anti-HBsAg antibody detected a band at 25.4 kDa in the positive control (without the endoplasmic reticulum (ER) retention sequence) and a band at 26.1 kDa in the transformants, while no signal was observed in wild-type F. velutipes. The HBsAg expression level in the fruiting bodies of these three transformants was determined by ELISA (Fig. 6).
Due to severe weather conditions no blood was collected in the 12th and 16th week.

Table 1. Serum anti-HBsAg antibodies detected in pig

| Group   | Pig code (gender) | t/week | N(antibody)/mIU/mL |
|---------|-------------------|--------|-------------------|
|         |                   | 6      | 8                 | 10    | 14   | 18    | 20    |
| Control |                   |        |                   |       |      |       |       |
| 16113 (F)| 2.00             | 2.00   | 2.00              | 2.00  | 2.00 | 2.00  | 2.00  |
| 17202 (M)| 2.00             | 2.00   | 2.00              | 2.00  | 2.00 | 2.00  | 2.00  |
| 17204 (M)| 2.00             | 2.00   | 2.00              | 2.00  | 2.00 | 2.00  | 2.00  |
| 16114 (F)| 2.00             | 2.00   | 2.00              | 2.00  | 2.00 | 2.00  | 2.00  |
| 17215 (F)| 2.00             | 2.00   | 2.00              | 2.00  | 2.00 | 3.97  | 39.87 |
| 15903 (M)| 2.00             | 2.00   | 5.36              | 14.90 | 2.00 | 2.00  | 2.00  |
| 17308 (M)| 2.00             | 2.00   | 2.00              | 2.00  | 2.00 | 2.00  | 2.00  |

mIU=milli-international units, F=female, M=male

Due to severe weather conditions no blood was collected in the 12th and 16th week.
Several studies have suggested that increased immunogenicity of HBsAg using oral administration via transgenic potatoes and tomatoes usually requires an adjuvant, such as cholera toxin (CT). Richter et al. (5) reported that feeding mice with 5 µg HBsAg expressed in potato tuber and 10 µg CT prompted a serum response peaking at approx. 70 mIU/mL. In the absence of adjuvant, primary immunization with 40 µg oral doses of potato-expressed antigen did not induce a response (6), but otherwise with 60 µg oral doses antigen prompted an antibody response up to 170 mIU/mL (26). In this study, a positive response was obtained by feeding transgenic *F. velutipes* fruiting bodies without CT, indicating that the mushroom polysaccharides might serve the role of an adjuvant. This observation is consistent with the report of Ichinohe et al. (14), who demonstrated the effectiveness of mycelial extracts derived from edible mushrooms as adjuvants for an intranasal influenza vaccine.

**CONCLUSION**

In this study, we obtained stable HBsAg transgenic *F. velutipes* dikaryotic mycelia via a mating scheme and confirmed that the production of anti-HBsAg antibodies was stimulated in pigs by feeding them *F. velutipes* fruiting bodies, demonstrating the potential of the application of *F. velutipes* in oral vaccines. This is the first report to show that the immunogenicity in pigs can be achieved by feeding them transgenic HBsAg mushroom.

**ACKNOWLEDGEMENTS**

The assistance of Dr Szu-Ming Chen (New Taipei City, Taiwan) in measuring the anti-HBsAg antibodies is greatly appreciated.

**FUNDING**

No external funding was received.

**CONFLICT OF INTEREST**

LHH is a current employee, and YTL and CLG are former employees of MycoMagic Biotechnology Co., Ltd. HYL is a former graduate student advised by CTH at National Taiwan University. CTH is bound with a Technology Transfer Agreement between MycoMagic and National Taiwan University (09T-101203-1N-A). The authors have declared that there are no other competing interests.

**ETHICS APPROVAL**

All animal tests were conducted by the Animal Technology Laboratories, Agriculture Technology Research Institute (Contract No.: BL-11-T020801-P) and were in compliance with Laboratory Animal Welfare and Ethics guidelines as issued by the Council of Agriculture, Taiwan. The protocol was approved by the Committee on Laboratory Animal Management of Agriculture Technology Research Institute, Taiwan.

**REFERENCES**

1. Daniell H, Streatfield SJ, Wycoff K. Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants. Trends Plant Sci. 2001;6(5):219-26. https://doi.org/10.1016/S1360-1385(01)01922-7
2. Pniewski T. Is an oral plant-based vaccine against hepatitis B virus possible? Curr Pharm Biotechnol. 2012;13(15):2692-704. https://doi.org/10.2174/138920112804724837
3. Arntzen CJ. High-tech herbal medicine: plant-based vaccines. Nat Biotechnol. 1997;15(3):221-2. https://doi.org/10.1038/nbt0397-221
4. Joung YH, Park SH, Moon KB, Jeon JH, Cho HS, Kim HS. The last ten years of advancements in plant-derived recombinant vaccines against hepatitis B. Int J Mol Sci. 2016;17(10): Article no. 1715. https://doi.org/10.3390/ijms17101715
5. Richter LJ, Thanavala Y, Arntzen CJ, Mason HS. Production of hepatitis B surface antigen in transgenic plants for oral immunization. Nat Biotechnol. 2000;18(11):1167-71. https://doi.org/10.1038/81153
6. Kong Q, Richter L, Yang YF, Arntzen CJ, Mason HS, Thanavala Y. Oral immunization with hepatitis B surface antigen expressed in transgenic plants. Proc Natl Acad Sci USA. 2001;98(20):11539-44. https://doi.org/10.1073/pnas.191617598
7. Gao Y, Ma Y, Li M, Cheng T, Li SW, Zhang J, et al. Oral immunization of animals with transgenic cherry tomatillo expressing HBsAg. World J Gastroenterol. 2003;9(5):996-1002. https://doi.org/10.3748/wjg.v9.i5.996
8. Huang Z, Mason HS. Conformational analysis of hepatitis B surface antigen fusions in an Agrobacterium-mediated transient expression system. Plant Biotechnol J. 2004;2(3):241-9. https://doi.org/10.1111/j.1467-7652.2004.00068.x
9. Kumar GBS, Ganapathi TR, Revathi CJ, Srinivas L, Bapat VA. Expression of hepatitis B surface antigen in transgenic banana plants. Planta. 2005;222(3):484-93. https://doi.org/10.1007/s00425-005-1556-y
10. Gleba Y, Klimyuk V, Marillonnet S. Viral vectors for the expression of proteins in plants. Curr Opin Biotechnol. 2007;18(2):134-41. https://doi.org/10.1016/j.copbio.2007.03.002
11. Mett V, Farrance CE, Green BJ, Yusibov V. Plants as biofactories. Biologicals. 2008;36(6):354-8. https://doi.org/10.1016/j.biologicals.2008.09.001
12. Tiwari S, Verma PC, Singh PK, Tuli R. Plants as bioreactors for the production of vaccine antigens. Biotechnol Adv. 2009;27(4):449-67. https://doi.org/10.1016/j.biotechadv.2009.03.006
13. Kilaru S, Collins CM, Hartley AJ, Bailey AM, Foster GD. Establishing molecular tools for genetic manipulation of the pleuromutilin-producing fungus Clitopilus passeckerianus. Appl Environ Microb. 2009;75(22):7196-204. https://doi.org/10.1128/AEM.01151-09

14. Ichinohe T, Ainaì A, Nakamura T, Akiyama Y, Maeyama J, Oda-giri T, et al. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia. J Med Virol. 2010;82(1):128-37. https://doi.org/10.1002/jmv.21670

15. Pérez-Martínez AS, Acevedo-Padilla SA, Bibbians-Martínez M, Galván-Alonso J, Rosales-Mendoza S. A perspective on the use of Pleurotus for the development of convenient fungi-made oral subunit vaccines. Vaccine. 2015;33(1):25-33. https://doi.org/10.1016/j.vaccine.2014.10.059

16. Lin YJ, Huang LH, Huang CT. Enhancement of heterologous gene expression in Flammulina velutipes using polycistronic vectors containing a viral 2A cleavage sequence. PLoS One. 2013;8(3):e59099. https://doi.org/10.1371/journal.pone.0059099

17. Lin YJ, Liu WT, Stark H, Huang CT. Expression of enterovirus 71 virus-like particles in transgenic enoki (Flammulina velutipes). Appl Microbiol Biotechnol. 2015;99(16):6765-74. https://doi.org/10.1007/s00253-015-6588-z

18. Petersen RH, Hughes KW, Redhead SA, Psurtseva N, Methven AS. Mating systems in the Xerulaceae (Agaricales, Basidiomycota): Flammulina. Mycoscience. 1999;40(5):411-26. https://doi.org/10.1007/BF02464396

19. van Peer AF, Park SY, Shin PG, Jang KY, Yoo YB, Park YJ, et al. Comparative genomics of the mating-type loci of the mushroom Flammulina velutipes reveals widespread synteny and recent inversions. PLoS One. 2011;6(7):e22249. https://doi.org/10.1371/journal.pone.0022249

20. Chen X, Stone M, Schlagnhauffer C, Romaine CP. A fruiting body tissue method for efficient Agrobacterium-mediated transformation of Agaricus bisporus. Appl Environ Microb. 2000;66(10):4510-3. https://doi.org/10.1128/AEM.66.10.4510-4513.2000

21. Kuo CY, Chou SY, Huang CT. Cloning of glycerolaldehyde-3-phosphate dehydrogenase gene and use of the gpd promoter for transformation in Flammulina velutipes. Appl Microbiol Biotechnol. 2004;65(5):593-9. https://doi.org/10.1007/s00253-004-1635-1

22. Kuo CY, Chou SY, Hseu RS, Huang CT. Heterologous expression of EGFP in enoki mushroom Flammulina velutipes. Bot Stud. 2010;51:303-9.

23. Kapusta J, Modelska A, Figlerowicz M, Pniewski T, Letellier M, Lisowa O, et al. A plant-derived edible vaccine against hepatitis B virus. FASEB J. 1999;13(13):1796-9. https://doi.org/10.1096/fasebj.13.13.1796

24. Huovila AP, Eder AM, Fuller SD. Hepatitis B surface antigen assembles in a post-ER, pre-Golgi compartment. J Cell Biol. 1992;118(6):1305-20. https://doi.org/10.1083/jcb.118.6.1305

25. Le Bouvier GL. Subtypes of hepatitis B antigen: clinical relevance? Ann Intern Med. 1973;79(6):894-6. https://doi.org/10.7326/0003-4819-79-6-894

26. Rukavtsova EB, Rudenko NV, Puchko EN, Zakharchenko NS, Buryanov YI. Study of the immunogenicity of hepatitis B surface antigen synthesized in transgenic potato plants with increased biosafety. J Biotechnol. 2015;203:84-8. https://doi.org/10.1016/j.jbiotec.2015.03.019